Project Grant R01AI196741
- Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $197,500 Project Grant to Georgia State University Research Foundation Inc. on April 22, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The project, titled "Cross-Protective Immune-Enhancing Mechanisms of Combined mRNA and Conventional Flu Vaccines," will be conducted in Atlanta, Georgia, with a completion date of March 31, 2028. The research focuses on...
- Federal Project Grant Award Summary Georgia TECH Research Corp received a $390,942 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective June 12, 2025, with a completion date of May 31, 2030. The project focuses on the research and development of self-assembled peptide nanoparticles (SAPNs) as a universal influenza vaccine platform. The research effort addresses the limitation...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Georgia State University Research Foundation Inc. a Project Grant of $6.68 million under the Allergy and Infectious Diseases Research program (CFDA 93.855) on August 18, 2025, with completion targeted for July 31, 2029. The project focuses on developing inhibitors of seasonal and pandemic influenza viruses by advancing prodrug conjugates of 4'-fluorouridine (4'-FLU), a pyrimidine...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Georgia Research Foundation, Inc. a Project Grant of $400,932 under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective February 2, 2026, through January 31, 2028. This exploratory research grant supports investigative work to identify immune cell types and cytokine profiles responsible for vaccine-induced protective immunity against cryptococcal...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $661,313 Project Grant (R01) to Massachusetts General Hospital on February 6, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support research on universal influenza vaccine development. Led by Principal Investigator Dr. Daniel Lingwood with Co-Investigator Dr. Andrew Ward from Scripps Research Institute, the project aims to develop a pan-influenza A vaccine...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Georgia State University Research Foundation Inc. a Project Grant of $434,938 under the Allergy and Infectious Diseases Research program (CFDA 93.855) for research conducted in Atlanta, Georgia. The award, dated February 19, 2026, with an ultimate completion date of January 31, 2028, supports the development of nanobodies (single-domain antibodies) as therapeutic agents against the highly...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Georgia Research Foundation, Inc. a Project Grant totaling $415,250 under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective August 21, 2025, with completion targeted for July 31, 2027. This research initiative addresses critical gaps in understanding gram-negative bacterial resistance mechanisms by investigating the feedback signaling system that...
- Federal Grant Award Summary The University of Nebraska received a $799,792 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective April 1, 2026 through March 31, 2031. This award funds the development of a universal influenza vaccine targeting pandemic prevention through novel immunogenic strategies. The research combines multiple vaccine design approaches, integrating immunodominant...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $182,422 Project Grant to the University of Washington, effective April 1, 2026, through March 31, 2031, under the Allergy and Infectious Diseases Research program (CFDA 93.855). This award supports a K01 Research Career Development initiative focused on enhancing influenza vaccine effectiveness through genetic surveillance and improved antigenic matching. The principal investigator...
- Federal Grant Award Summary Emory University received a $711,555 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective May 13, 2025, through April 30, 2030. The project delivers an integrated research and development framework combining graph neural networks with traditional compartmental models to advance understanding of spatiotemporal transmission dynamics and control...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded $805,866 to the University of Georgia Research Foundation, Inc. on May 12, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop and validate advanced predictive models for influenza vaccine responses. The project, which extends through April 30, 2031, will deliver statistical and machine-learning models that incorporate longitudinal antibody response data and heterologous strain information to improve predictions of vaccine effectiveness across diverse populations. The research addresses critical limitations in existing predictive approaches by integrating dynamic immune system data beyond pre-vaccination baseline measurements and accounting for non-vaccine-specific antibody responses, thereby enabling more accurate and adaptable vaccine efficacy predictions across multiple influenza viral strains. The deliverables under this award include predictive models that forecast both vaccine-strain-specific responses and heterologous breadth of antibody reactions, with the ultimate goal of supporting tailored vaccination strategies. This research directly advances the program's objective to support investigator-initiated biomedical research that improves understanding of infectious disease mechanisms and enhances vaccine development approaches, contributing to public health outcomes through enhanced personalization of influenza vaccination strategies and improved protection efficacy prediction.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $805.9k | 5/12/26 |